MANAGEMENT DISCUSSION AND ANALYSIS
FY 2025-26 presented a challenging operating environment, marked by pricing pressure in domestic markets and demand softness in select product categories. Against this backdrop, the Company delivered a resilient performance-protecting margins, strengthening its regulatory standing, and laying the groundwork for meaningful revenue growth in the years ahead.
Industry Environment
The pharmaceutical API sector continued to face headwinds during the year, including elevated input costs driven by global commodity market volatility, competitive pricing in the domestic market due to surplus supply, and subdued demand in certain markets. Despite these conditions, export markets offered relatively better price realisation, and the Company oriented its business mix accordingly.
A notable trend that has intensified in recent years is the entry of non-traditional players into the API space. These entrants have, in several instances, pursued aggressive pricing strategies-at times pricing below manufacturing cost-with the objective of rapidly gaining market share. While many such participants do not sustain operations over the medium term, the pricing distortion they create in the interim affects the entire industry, including established manufacturers with sound fundamentals. The Company has chosen not to compete on this basis, prioritising margin integrity and longterm customer relationships over participation in unsustainable price competition.
Input costs, particularly for key raw materials, remained elevated through much of the year. The Company responded through a combination of alternative sourcing, supplier negotiations, and ongoing backward integration initiatives, which helped partially offset the impact on margins.
Financial Performance Overview
The following table provides a summary of key financial metrics for FY 2025-26. A detailed discussion of operational performance, revenue, margins, and cost efficiency is provided in the Operational Performance and State of Companys Affairs section of this report.
| (Rs in lakhs) | ||
Metric |
FY 2025-26 | FY 2024-25 |
Revenue from Operations |
10,196.71 | 12,600.79 |
EBITDA |
1,316.01 | 1,227.10 |
EBITDA Margin |
12.89% | 9.73% |
Profit Before Tax |
466.43 | Rs. 490.00 |
Profit After Tax |
342.57 | Rs. 356.29 |
Despite lower revenues, EBITDA margin expanded by 316 basis points to 12.89%, reflecting the quality of the Companys operational decisions during the year. The marginal decline in PAT is attributable to a one-time exceptional provision related to the new Labour Codes and does not reflect underlying business performance.
Finished Dosage Formulations (FDF) Division
At the end of FY 2025-26, the Company took a considered management decision to discontinue its Finished Dosage Formulations (FDF) business unit. The FDF division had operated at a limited scale and, upon review, was determined to be non-core to the Companys strategic focus on Active Pharmaceutical Ingredient (API) manufacturing. Discontinuing the division allows the Company to concentrate its resources, management attention, and capital toward its core API business. The process of wind-down of FDF operations will be completed during the current year.
Regulatory Strategy and Global Expansion
The receipt of EDQM approval during the year marks a turning point in the Companys international growth trajectory. European markets and the many countries globally that align their pharmaceutical import standards with EDQM certification now become accessible to the Company. Management is actively building the commercial relationships needed to capitalise on this opening in not only European markets but other aligned markets as well.
The Company is expanding its Drug Master File (DMF) portfolio across multiple jurisdictions-Europe, Brazil, and Korea-progressively qualifying its products for entry into high-value regulated markets. Company is soon expecting regulatory inspection by ANVISA, Brazil . Management is confident in the Companys compliance readiness and views a favourable outcome of the inspection as an important milestone toward establishing a presence in one of the worlds largest pharmaceutical markets in South America.
Outlook
The Company looks ahead to FY 2026-27 with a clear sense of direction and a broader range of growth opportunities than at any point in its recent history.
The EDQM approval has opened doors beyond the traditional API export business. The Company has begun onboarding customers in the Contract Research and Manufacturing Services (CRAMS) space-a segment characterised by better margins, faster turnaround cycles, and deeper customer relationships than standard API supply. The Company sees significant potential in this market and is actively expanding its presence. Several customer engagements are at advanced stages, and management expects CRAMS to become a meaningful contributor to revenue and profitability in the coming years.
In parallel, the Company is growing its business in the supply of intermediates to global API manufacturers. Historically, growth in this segment was constrained by the preference of large API manufacturers for suppliers whose materials are approvable across all of their global markets-a threshold the Companys products could not always meet. The EDQM and expected ANVISA approvals will materially changed this dynamics. With certain late-stage intermediates falling within regulatory purview, the Companys certified manufacturing standards are now a differentiator rather than a barrier. Acceptance of the Companys intermediates by large global API manufacturers has improved considerably, and this segment is now growing at a pace that reflects the pent-up demand from prior years.
Capital expenditure will remain moderate and routine unless significant new capacity requirements emerge, as the infrastructure investments of prior years have established a strong foundation.
The overarching objective for the year ahead is to grow revenues meaningfully aided by EDQM and ANVISA approvals , with a deliberate focus on products, segments, and markets that offer better margin profiles. The Board and Management remain committed to translating these operational and strategic improvements into sustainable returns for shareholders.
Cautionary Statement
Statements in this Management Discussion and Analysis describing the Companys objectives, projections, estimates, and expectations may constitute forward-looking statements within the meaning of applicable laws and regulations. Actual results may differ materially from those expressed or implied. The Company does not undertake to update these statements.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.